Enhanced clopidogrel response in smokers is reversed after discontinuation as assessed by VerifyNow assay: Additional evidence for the concept of 'smokers' paradox'

Heart

Volumn 98, Issue 13, 2012, Pages 1000-1006

  Park, Kyung Woo ^a   Kang, Si Hyuck ^a   Kang, Jeehoon ^a   Jeon, Ki Hyun ^a   Park, Jin Joo ^a   Han, Jung Kyu ^a   Koh, Jin Sin ^a   Lee, Sang Eun ^a   Yang, Han Mo ^a   Lee, Hae Young ^a   Kang, Hyun Jae ^a   Koo, Bon Kwon ^a   Oh, Byung Hee ^a   Park, Young Bae ^a   Kim, Hyo Soo ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PURINERGIC P2Y12 RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD SAMPLING; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POINT OF CARE TESTING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING CESSATION; SMOKING HABIT; THROMBOCYTE AGGREGATION INHIBITION;

AGED; BLOOD PLATELETS; CORONARY ANGIOGRAPHY; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING; SMOKING CESSATION; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84862019325     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-301565     Document Type: Article

References (36)

1. Bliden KP, Dichiara J, Lawal L, et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 2008;52:531-3.
2. Price MJ, Nayak KR, Barker CM, et al. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009;103:1339-43.
3. Gremmel T, Steiner S, Seidinger D, et al. Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy. Thromb Res 2009;124:588-91.
4. Park KW, Park JJ, Jeon KH, et al. Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans. Cardiovasc Ther 2012;30:5-11.
5. Park KW, Park JJ, Jeon KH, et al. Enhanced clopidogrel responsiveness in smokers: smokers' paradox is dependent on cytochrome P450 CYP1A2 status. Arterioscler Thromb Vasc Biol 2011;31:665-71.
6. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-5.
7. Jeong YH, Cho JH, Kang MK, et al. Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction. Thromb Res 2010;126:e334-8.
8. Berger JS, Bhatt DL, Steinhubl SR, et al. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation 2009;120:2337-44.
9. Desai NR, Mega JL, Jiang S, et al. Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 2009;53:1273-8.
10. Zhou SF, Wang B, Yang LP, et al. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 2010;42:268-354.
11. Ancrenaz V, Daali Y, Fontana P, et al. Impact of genetic polymorphisms and drugdrug interactions on clopidogrel and prasugrel response variability. Curr Drug Metab 2010;11:667-77.
12. Malinin A, Pokov A, Swaim L, et al. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 2006;28:315-22. (Pubitemid 44047198)
13. Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 2007;119:277-84. (Pubitemid 44918092)
14. Taira DA, Seto TB, Ho KK, et al. Impact of smoking on health-related quality of life after percutaneous coronary revascularization. Circulation 2000;102:1369-74.
15. Joint Commission on Accreditation of Healthcare Organizations. Joint Commission on Accreditation of Healthcare Organizations. 2004. http://www. jointcommission.org/core-measure-sets.aspx (accessed 15th Jul 2011).
16. Burling TA, Singleton EG, Bigelow GE, et al. Smoking following myocardial infarction: a critical review of the literature. Health Psychol 1984;3:83-96.
17. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 2004;76:178-84. (Pubitemid 39013407)
18. Patti G, Nusca A, Mangiacapra F, et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008;52:1128-33.
19. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009;119:237-42.
20. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-33.
21. Ibrahim JG, Lipsitz SR. Parameter estimation from incomplete data in binomial regression when the missing data mechanism is nonignorable. Biometrics 1996;52:1071-8. (Pubitemid 26296084)
22. Breet NJ, van Werkum JW, Bouman HJ, et al. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart 2011;97:983-90.
23. Park KW, Jeon KH, Kang SH, et al. Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study). Am J Cardiol 2011;108:1556-63.
24. Bouman HJ, Harmsze AM, van Werkum JW, et al. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart 2011;97:1239-44.
25. Gremmel T, Steiner S, Seidinger D, et al. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart 2010;96:186-9.
26. Lee SP, Bae JW, Park KW, et al. Inhibitory interaction between calcium channel blocker and clopidogrel. Efficacy of cilostazol to overcome it. Circ J 2011;75:2581-9.
27. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm 2007;64:1917-21. (Pubitemid 47462906)
28. Hochholzer W, Trenk D, Mega JL, et al. Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. Am Heart J 2011;162:518-26.e5.
29. Sibbald M, Yan AT, Huang W, et al. Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: insights from the global registry of acute coronary events. Am Heart J 2010;160:855-61.
30. Tantcheva-Poor I, Zaigler M, Rietbrock S, et al. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 1999;9:131-44. (Pubitemid 29358995)
31. Sachse C, Brockmoller J, Bauer S, et al. Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47:445-9. (Pubitemid 29161279)
32. Gunes A, Ozbey G, Vural EH, et al. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. Pharmacogenomics 2009;10:769-78.
33. Samet JM. The 1990 report of the surgeon general: the health benefits of smoking cessation. Am Rev Respir Dis 1990;142:993-4. (Pubitemid 20384347)
34. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable anginaesummary article: a report of the American College of Cardiology/American heart association Task Force on Practice guidelines (Committee on the management of patients with chronic stable angina). Circulation 2003;107:149-58. (Pubitemid 36070948)
35. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097-105.
36. Trenk D. Primary Results Of Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement On Clopidogrel To Guide Alternative Therapy With Prasugrel. San Francisco: Presented at the Transcatheter Cardiovascular Therapeutics Meeting, 2011.